Michael Moonwalks to Record-Breaking $200M+ Box Office Opening

Lionsgate’s biopic "Michael" opened to $97 million domestically and $217.4 million globally, setting a record for the biggest opening weekend ever for a musical biopic. The film also generated $13.8 million from IMAX domestically and posted strong audience scores, including an A- CinemaScore and 97% Popcornmeter. The result is Lionsgate’s biggest opening since 2015 and a notably strong start heading into the summer movie season.

Analysis

IMAX is the cleanest second-order winner here: premium-format demand is proving elastic even in a mixed critical environment, which matters because the format’s incremental margin is disproportionately high and the film’s audience skew suggests older, higher-spend consumers are willing to pay up for eventized content. The real signal is not the movie itself but the willingness of studios to keep funneling tentpole-sized marketing budgets into theatrical exclusives when a title can still clear a massive opening despite weak critic sentiment.

For Lionsgate, this is a rare de-risking event, but the market will likely overestimate how much one breakout changes the franchise value of the slate. The biopic’s economics still hinge on holdover compression over the next 2-4 weekends; if the multiple normalizes sharply, the gross can look great while equity capture remains muted because distribution and participation economics limit upside. The bigger beneficiary may be Universal’s offshore muscle, which reinforces that global distribution capabilities, not just production IP, are where incremental value accrues.

The contrarian angle is that strong audience scores can coexist with mediocre long-run monetization if the opening is front-loaded by fan concentration and premium screens. That creates a narrow window for IMAX and cinema-exposure names to outperform over the next few weeks, but not necessarily for the underlying studio to re-rate unless ancillary revenue and awards/holiday legs materially extend the theatrical tail. The key watch item is weekday decay: a steep drop would imply the opening was more event-driven than broad-based, which would cap follow-through.

Catalyst-wise, the next 7-14 days matter most for read-throughs on premium-screen demand and studio release strategy, while the next 1-3 months will tell us whether this is a one-off or evidence of a healthier theatrical slate. If the post-opening hold is above average, expect studios to lean harder into high-concept, nostalgia-driven titles and more IMAX allocations; if not, this becomes a short-lived sentiment trade with limited fundamental persistence.

Key Decisions for Investors

• Go long IMAX for the next 2-4 weeks on follow-through in premium-format demand; risk/reward is favorable if post-opening holds stay above average, but trim aggressively if weekday decays accelerate.
• Pair trade: long IMAX / short NFLX over the next 1-2 months to express a relative revival in theatrical eventization versus streaming substitution; thesis breaks if box office holdovers fail to sustain.
• Small tactical long LION/Lionsgate exposure for 1-3 months only if available via liquid proxy or call structure; treat as a sentiment trade, not a structural re-rate, and use a tight stop if the next weekend drop exceeds normal franchise-comparable ranges.
• Avoid chasing studio equities broadly; prefer a basket of cinema-enablement names over content owners, since premium-screen economics capture the cleaner incremental margin from the opening.
• If available, buy near-dated IMAX calls into the next box office weekend and monetize into any revised guidance or positive hold commentary; the setup has asymmetric upside but very short half-life.